Papilloma Viral Infection
9
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Communication Strategies to Increase HPV Vaccination Intention
Reducing Urban Cervical Cancer Disparities
Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening Programs
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV and Male Homosexuality in General Practice?
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Immunogenicity of Off-Schedule Dosing of HPV Vaccine